I came across this info today.
Mar 28 2024: "Protagonist Therapeutics said it plans to seek FDA approval for rusfertide for treating polycythemia vera in late 2025"
cancer.gov/news-events/canc...
and an explanation why it has taken so long, an FDA hold a few years ago:
Oct 2021 "The FDA has removed the full clinical hold that had previously been placed on trials evaluating rusfertide (PTG-300)"
They were monitoring mice on it and "found benign and malignant subcutaneous skin tumors" Seems ok in humans since trial resumed, but no doubt they are watching carefully. Sometimes they use very high doses in these sort of non-clinical studies, but it's not specified.
--
One application for Rusf may be HCT resistance on IFN, a problem we're seeing regularly on the forum.